Follow
Lillian Siu
Lillian Siu
Princess Margaret Cancer Centre
Verified email at uhn.ca
Title
Cited by
Cited by
Year
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
12932013
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ...
Journal of clinical oncology 19 (13), 3267-3279, 2001
12562001
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
12132017
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu
Journal of clinical oncology 22 (1), 77-85, 2004
9962004
Dose escalation methods in phase I cancer clinical trials
C Le Tourneau, JJ Lee, LL Siu
JNCI: Journal of the National Cancer Institute 101 (10), 708-720, 2009
9302009
Toward understanding and exploiting tumor heterogeneity
AA Alizadeh, V Aranda, A Bardelli, C Blanpain, C Bock, C Borowski, ...
Nature medicine 21 (8), 846-853, 2015
7682015
The statins as anticancer agents
KKW Chan, AM Oza, LL Siu
Clinical cancer research 9 (1), 10-19, 2003
7502003
Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L Khoja, D Day, TWW Chen, LL Siu, AR Hansen
Annals of Oncology 28 (10), 2377-2385, 2017
7362017
Deintensification candidate subgroups in human papillomavirus–related oropharyngeal cancer according to minimal risk of distant metastasis
B O'Sullivan, SH Huang, LL Siu, J Waldron, H Zhao, B Perez-Ordonez, ...
Journal of clinical oncology 31 (5), 543-550, 2013
6612013
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials
CA Townsley, R Selby, LL Siu
Journal of clinical oncology 23 (13), 3112-3124, 2005
6462005
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong …
AWM Lee, WH Lau, SY Tung, DTT Chua, R Chappell, L Xu, L Siu, ...
Journal of Clinical Oncology 23 (28), 6966-6975, 2005
6142005
Molecular profiling for precision cancer therapies
ER Malone, M Oliva, PJB Sabatini, TL Stockley, LL Siu
Genome medicine 12, 1-19, 2020
5512020
Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas
SH Huang, W Xu, J Waldron, L Siu, X Shen, L Tong, J Ringash, A Bayley, ...
J Clin Oncol 33 (8), 836-845, 2015
4242015
Randomized trial of radiotherapy plus concurrent–adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma
AWM Lee, SY Tung, DTT Chua, RKC Ngan, R Chappell, R Tung, L Siu, ...
Journal of the National Cancer Institute 102 (15), 1188-1198, 2010
4142010
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial
JJ Knox, D Hedley, A Oza, R Feld, LL Siu, E Chen, M Nematollahi, ...
Journal of Clinical Oncology 23 (10), 2332-2338, 2005
3812005
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ...
British journal of cancer 95 (9), 1148-1154, 2006
3792006
Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada
X Chen, LL Siu
Journal of Clinical Oncology 19 (23), 4291-4297, 2001
3712001
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma
W Shi, H Kato, B Perez-Ordonez, M Pintilie, S Huang, A Hui, B O'Sullivan, ...
Journal of Clinical Oncology 27 (36), 6213-6221, 2009
3682009
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with …
M Moore, HW Hirte, L Siu, A Oza, SJ Hotte, O Petrenciuc, F Cihon, ...
Annals of oncology 16 (10), 1688-1694, 2005
3652005
Circulating tumor DNA and liquid biopsy in oncology
DW Cescon, SV Bratman, SM Chan, LL Siu
Nature Cancer 1 (3), 276-290, 2020
3632020
The system can't perform the operation now. Try again later.
Articles 1–20